skip navigation


Abstract Database

Register for Latest Research

Stay Informed
Register with NCJRS to receive NCJRS's biweekly e-newsletter JUSTINFO and additional periodic emails from NCJRS and the NCJRS federal sponsors that highlight the latest research published or sponsored by the Office of Justice Programs.

NCJRS Abstract

To download this abstract, check the box next to the NCJ number then click the "Back To Search Results" link. Then, click the "Download" button on the Search Results page. Also see the Obtain Documents page for direction on how to access resources online, via mail, through interlibrary loans, or in a local library.


NCJ Number: 250778 
Title: Reports of Adverse Events Associated With Use of Novel Psychoactive Substances, 2013–2016: A Review
Author(s): Barry K. Logan; Amanda L.A. Mohr; Melissa Friscia; Alex J. Krotulski; Donna M. Papsun; Sherri L. Kacinko; Jeri D. Ropero-Miller; Marilyn A. Huestis
Date Published: April 2017
Page Count: 38
Sponsoring Agency: National Institute of Justice (NIJ)
Washington, DC 20531
Grant Number: 2011-DN-BX-K564
Sale Source: National Institute of Justice (NIJ)
US Department of Justice
Office of Justice Programs
810 Seventh Street NW
Washington, DC 20531
United States of America
Document: PDF
Format: Brochure/Pamphlet; Document (Online)
Language: English
Country: United States of America
Annotation: This article documents and discusses adverse effects of intoxications from novel psychoactive substances (NPS) such as cannabinoids, stimulants, hallucinogens, benzodiazepines, and opioids, spanning January 2013 through December 2016.
Abstract: These data are based on reports of emergency departments, death investigations, impaired driving cases, and other forensic contexts. A summary is provided on the chemistry, pharmacology, and adverse events associated with novel drug classes. Adverse effects of symptoms linked to ingestion of more than 45 NPS are categorized in tables that include data on demographics, case history, clinical or behavioral symptoms, autopsy findings, and drug confirmations with quantitative results. Based on these findings and gaps in the available data, the article outlines recommendations for future toxicological testing for evolving substances. Among the recommendations are the development and management of a national monitoring program that provides real-time clinical and toxicological data, confirmed analytically, on emerging drugs and their known toxidromes and side effects. It is also recommended that there be increased efforts to confirm analytically the agents responsible for clinical intoxications that involve adverse events in emergency department admissions or hospitalizations. In addition, evidence-based community preparedness among analytical laboratories must be improved for the sharing of toxicological findings and trends in NPS, so as to enable early detection of new drugs in forensic and clinical populations.
Main Term(s): Drugs
Index Term(s): Benzodiazepines; Drug effects; Drug overdose; Hallucinogens; Marijuana; NIJ grant-related documents; NIJ Resources; Opioids
To cite this abstract, use the following link:

*A link to the full-text document is provided whenever possible. For documents not available online, a link to the publisher's website is provided. Tell us how you use the NCJRS Library and Abstracts Database - send us your feedback.